RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes

No Thumbnail
Authors
Ristić-Medić, Danijela K.
Peruničić-Peković, Gordana
Rašić-Milutinović, Zorica
Article (Published version)
Metadata
Show full item record
Abstract
In general, patients with end-stage renal disease treated with chronic hemodialysis have plasma and cell membrane fatty acid profiles that indicate essential fatty acid deficiency, with low omega (n)-3 and n-6 polyunsaturated fatty acid products, including dihomo-γ-linolenic, arachidonic, and eicosapentaenoic and docosahexaenoic acids. Abnormal fatty acid metabolism in hemodialysis patients may contribute to clinical problems such as itching, abnormal perspiration, susceptibility to infection, delayed wound healing, anemia, and increased incidence of cardiovascular events. By modulating cell membrane structure and function as well as synthesis of lipid mediators such as eicosanoids, n-3 polyunsaturated fatty acid supplementation may offer multiple health benefits to dialysis patients based on antiinflammatory and cardioprotective effects. The present review summarizes what is known about the concentration of polyunsaturated fatty acids in hemodialysis patients and evaluates the effects... of n-3 polyunsaturated fatty acid supplementation from randomized controlled studies designed with the purpose of identifying the link between polyunsaturated fatty acid levels and clinical outcomes in end-stage renal disease. There are many limitations in the published studies which deal with changes in fatty acid metabolism and polyunsaturated fatty acid content in chronic renal failure. However, in general, it can be concluded that patients on hemodialysis need nutritional care programs with an adequate n-6/n-3 polyunsaturated fatty acid ratio in their diet. In fact, further well-designed and controlled studies are needed to confirm that n-3 polyunsaturated fatty acid supplementation might reduce the progression of chronic kidney disease and eliminate some clinical problems in hemodialysis patients.

Keywords:
Chronic kidney disease / Hemodialysis / Phospholipid fatty acid / Polyunsaturated fatty acid
Source:
Nutritional Therapy & Metabolism, 2011, 29, 4, 178-191

DOI: 10.5301/NTM.2012.9662

ISSN: 1828-6232

Scopus: 2-s2.0-84867525316
[ Google Scholar ]
7
URI
http://rimi.imi.bg.ac.rs/handle/123456789/380
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Ristić-Medić, Danijela K.
AU  - Peruničić-Peković, Gordana
AU  - Rašić-Milutinović, Zorica
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/380
AB  - In general, patients with end-stage renal disease treated with chronic hemodialysis have plasma and cell membrane fatty acid profiles that indicate essential fatty acid deficiency, with low omega (n)-3 and n-6 polyunsaturated fatty acid products, including dihomo-γ-linolenic, arachidonic, and eicosapentaenoic and docosahexaenoic acids. Abnormal fatty acid metabolism in hemodialysis patients may contribute to clinical problems such as itching, abnormal perspiration, susceptibility to infection, delayed wound healing, anemia, and increased incidence of cardiovascular events. By modulating cell membrane structure and function as well as synthesis of lipid mediators such as eicosanoids, n-3 polyunsaturated fatty acid supplementation may offer multiple health benefits to dialysis patients based on antiinflammatory and cardioprotective effects. The present review summarizes what is known about the concentration of polyunsaturated fatty acids in hemodialysis patients and evaluates the effects of n-3 polyunsaturated fatty acid supplementation from randomized controlled studies designed with the purpose of identifying the link between polyunsaturated fatty acid levels and clinical outcomes in end-stage renal disease. There are many limitations in the published studies which deal with changes in fatty acid metabolism and polyunsaturated fatty acid content in chronic renal failure. However, in general, it can be concluded that patients on hemodialysis need nutritional care programs with an adequate n-6/n-3 polyunsaturated fatty acid ratio in their diet. In fact, further well-designed and controlled studies are needed to confirm that n-3 polyunsaturated fatty acid supplementation might reduce the progression of chronic kidney disease and eliminate some clinical problems in hemodialysis patients.
T2  - Nutritional Therapy & Metabolism
T1  - PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes
EP  - 191
IS  - 4
SP  - 178
VL  - 29
DO  - 10.5301/NTM.2012.9662
UR  - conv_5264
ER  - 
@article{
author = "Ristić-Medić, Danijela K. and Peruničić-Peković, Gordana and Rašić-Milutinović, Zorica",
year = "2011",
abstract = "In general, patients with end-stage renal disease treated with chronic hemodialysis have plasma and cell membrane fatty acid profiles that indicate essential fatty acid deficiency, with low omega (n)-3 and n-6 polyunsaturated fatty acid products, including dihomo-γ-linolenic, arachidonic, and eicosapentaenoic and docosahexaenoic acids. Abnormal fatty acid metabolism in hemodialysis patients may contribute to clinical problems such as itching, abnormal perspiration, susceptibility to infection, delayed wound healing, anemia, and increased incidence of cardiovascular events. By modulating cell membrane structure and function as well as synthesis of lipid mediators such as eicosanoids, n-3 polyunsaturated fatty acid supplementation may offer multiple health benefits to dialysis patients based on antiinflammatory and cardioprotective effects. The present review summarizes what is known about the concentration of polyunsaturated fatty acids in hemodialysis patients and evaluates the effects of n-3 polyunsaturated fatty acid supplementation from randomized controlled studies designed with the purpose of identifying the link between polyunsaturated fatty acid levels and clinical outcomes in end-stage renal disease. There are many limitations in the published studies which deal with changes in fatty acid metabolism and polyunsaturated fatty acid content in chronic renal failure. However, in general, it can be concluded that patients on hemodialysis need nutritional care programs with an adequate n-6/n-3 polyunsaturated fatty acid ratio in their diet. In fact, further well-designed and controlled studies are needed to confirm that n-3 polyunsaturated fatty acid supplementation might reduce the progression of chronic kidney disease and eliminate some clinical problems in hemodialysis patients.",
journal = "Nutritional Therapy & Metabolism",
title = "PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes",
pages = "191-178",
number = "4",
volume = "29",
doi = "10.5301/NTM.2012.9662",
url = "conv_5264"
}
Ristić-Medić, D. K., Peruničić-Peković, G.,& Rašić-Milutinović, Z.. (2011). PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes. in Nutritional Therapy & Metabolism, 29(4), 178-191.
https://doi.org/10.5301/NTM.2012.9662
conv_5264
Ristić-Medić DK, Peruničić-Peković G, Rašić-Milutinović Z. PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes. in Nutritional Therapy & Metabolism. 2011;29(4):178-191.
doi:10.5301/NTM.2012.9662
conv_5264 .
Ristić-Medić, Danijela K., Peruničić-Peković, Gordana, Rašić-Milutinović, Zorica, "PUFA status and omega-3 fatty acid supplementation in hemodialysis patients: Pathophysiological aspects and clinical outcomes" in Nutritional Therapy & Metabolism, 29, no. 4 (2011):178-191,
https://doi.org/10.5301/NTM.2012.9662 .,
conv_5264 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB